A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 335-344

  Fry, Simon A ^a   Sinclair, John ^b   Timms, John F ^b   Leathem, Anthony J ^b   Dwek, Miriam V ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Breast cancer; Glycosylation; Metastasis

Indexed keywords

AGGLUTININ; GLYCOPROTEIN; TUMOR MARKER; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN TARGETING;

ADULT; AGED; ANTIGENS, CD; BREAST NEOPLASMS; CADHERINS; FEMALE; GLYCOPROTEINS; HUMANS; LECTINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROTEIN BINDING; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

HELIX POMATIA;

EID: 84870358210     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.011     Document Type: Article

References (51)

1. Forouzanfar M.H., Foreman K.J., Delossantos A.M., Lozano R., Lopez A.D., Murray C.J., Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 1980, 378(2011):1461-1484.
2. Benson J.R., Jatoi I., Keisch M., Esteva F.J., Makris A., Jordan V.C. Early breast cancer. Lancet 2009, 373:1463-1479.
3. Weigelt B., Peterse J.L., van't Veer L.J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 2005, 5:591-602.
4. Weigel M.T., Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer 2010, 17:R245-R262.
5. Duffy M.J., Evoy D., McDermott E.W. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin. Chim. Acta 2010, 411:1869-1874.
6. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608:1-22.
7. Duffy M.J. Serum tumour markers in breast cancer: are they of clinical value?. Clin. Chem. 2006, 52:345-351.
8. Dai J., Allard W.J., Davis G., Yeung K.K. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin. Tumour Biol. 1998, 19:100-110.
9. Drake P.M., Cho W., Li B., Prakobphol A., Johansen E., Anderson N.L., Regnier F.E., Gibson B.W., Fisher S.J. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010, 56:223-236.
10. Lowe J.B., Marth J.D. A genetic approach to Mammalian glycan function. Annu. Rev. Biochem. 2003, 72:643-691.
11. Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 1820, 2012:1347-1353.
12. Brooks S.A., Carter T.M., Royle L., Harvey D.J., Fry S.A., Kinch C., Dwek R.A., Rudd P.M. Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. Anticancer Agents Med. Chem. 2008, 8:2-21.
13. Dwek M.V., Jenks A., Leathem A.J. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin. Chim. Acta 2010, 411:1935-1939.
14. Abd Hamid U.M., Royle L., Saldova R., Radcliffe C.M., Harvey D.J., Storr S.J., Pardo M., Antrobus R., Chapman C.J., Zitzmann N., Robertson J.F., Dwek R.A., Rudd P.M. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18:1105-1118.
15. Kyselova Z., Mechref Y., Kang P., Goetz J.A., Dobrolecki L.E., Sledge G.W., Schnaper L., Hickey R.J., Malkas L.H., Novotny M.V. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin. Chem. 2008, 54:1166-1175.
16. Yang Z., Harris L.E., Palmer-Toy D.E., Hancock W.S. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin. Chem. 2006, 52:1897-1905.
17. Zeng Z., Hincapie M., Pitteri S.J., Hanash S., Schalkwijk J., Hogan J.M., Wang H., Hancock W.S. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal. Chem. 2011, 83:4845-4854.
18. Sanchez J.F., Lescar J., Chazalet V., Audfray A., Gagnon J., Alvarez R., Breton C., Imberty A., Mitchell E.P. Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold. J. Biol. Chem. 2006, 281:20171-20180.
19. Markiv D., Peiris G.P., Curley M., Odell M.V., Dwek Identification, cloning, and characterization of two N-acetylgalactosamine-binding lectins from the albumen gland of Helix pomatia. J. Biol. Chem. 2011, 286:20260-20266.
20. Saint-Guirons J., Zeqiraj E., Schumacher U., Greenwell P., Dwek M. Proteome analysis of metastatic colorectal cancer cells recognized by the lectin Helix pomatia agglutinin. Proteomics 2007, 7:4082-4089.
21. Rambaruth N.D., Greenwell P., Dwek M.V. The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer. Glycobiology 2012, 22:839-848.
22. Mitchell B.S., Schumacher U. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Histol. Histopathol. 1999, 14:217-226.
23. Brooks S.A. The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol. Histopathol. 2000, 15:143-158.
24. Schumacher U., Adam E. Lectin histochemical HPA-binding pattern of human breast and colon cancers is associated with metastases formation in severe combined immunodeficient mice. Histochem. J. 1997, 29:677-684.
25. Dwek M.V., Ross H.A., Streets A.J., Brooks S.A., Adam E., Titcomb A., Woodside J.V., Schumacher U., Leathem A.J. Helix pomatia agglutinin lectin-binding oligosaccharides of aggressive breast cancer. Int. J. Cancer 2001, 95:79-85.
26. Brooks S.A., Leathem A.J. Expression of N-acetyl galactosaminylated and sialylated glycans by metastases arising from primary breast cancer. Invasion Metastasis 1998, 18:115-121.
27. Welinder C., Jansson B., Ferno M., Olson H., Baldetorp B. Expression of Helix pomatia lectin binding glycoproteins in women with breast cancer in relationship to their blood group phenotypes. J. Proteome Res. 2009, 8:782-787.
28. Gharbi S., Gaffney P., Yang A., Zvelebil M.J., Cramer R., Waterfield M.D., Timms J.F. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell Proteomics 2002, 1:91-98.
29. Julenius K., Mølgaard A., Gupta R., Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 2005, 15:153-164.
30. Teng H., Zhang W.Y., Zhu F.Q. A study on the serum pregnancy zone protein levels in pregnant women and patients with gynecological tumors. Chin. Med. J. 1994, 107:910-914.
31. Petersen C.M., Jensen P.H., Bukh A., Sunde L., Lamm L.U., Ingerslev J. Pregnancy zone protein: a re-evaluation of serum levels in healthy women and in women suffering from breast cancer or trophoblastic disease. Scand. J. Clin. Lab. Invest. 1990, 50:479-485.
32. Sulkowska M., Famulski W., Wincewicz A., Moniuszko T., Kedra B., Koda M., Zalewski B., Baltaziak M., Sulkowski S. Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori 2006, 92:67-71.
33. Streets A.J., Brooks S.A., Dwek M.V., Leathem A.J. Identification, purification and analysis of a 55kDa lectin binding glycoprotein present in breast cancer tissue. Clin. Chim. Acta 1996, 254:47-61.
34. Harris J.P., Caleb M.H., South M.A. Secretory component in human mammary carcinoma. Cancer Res. 1975, 35:1861-1864.
35. Brooks J.J., Ernst C.S. Immunoreactive secretory component of IgA in human tissues and tumors. Am. J. Clin. Pathol. 1984, 82:660-665.
36. Ahmad S., Faruqi N.A., Arif S.H., Akhtar S. Serum immunoglobulin levels in neoplastic disorder of breast. J. Indian Med. Assoc. 2002, 100:495-496.
37. Ijsselstijn L., Dekker L.J., Stingl C., van der Weiden M.M., Hofman A., Kros J.M., Koudstaal P.J., Sillevis Smitt P.A., Ikram M.A., Breteler M.M., Luider T.M. Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. J. Proteome Res. 2011, 10:4902-4910.
38. Jung K., Cho W., Regnier F.E. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. J. Proteome Res. 2009, 8:643-650.
39. Labelle M., Schnittler H.J., Aust D.E., Friedrich K., Baretton G., Vestweber D., Breier G. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signalling. Cancer Res. 2008, 68:1388-1397.
40. Johann D.J., Wei B.R., Prieto D.A., Chan K.C., Ye X., Valera V.A., Simpson R.M., Rudnick P.A., Xiao Z., Issaq H.J., Linehan W.M., Stein S.E., Veenstra T.D., Blonder J. Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal. Chem. 2010, 82:1584-1588.
41. Hendrix M.J., Seftor E.A., Meltzer P.S., Gardner L.M., Hess A.R., Kirschmann D.A., Schatteman G.C., Seftor R.E. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. USA 2001, 98:8018-8023.
42. Zhang L.Z., Mei J., Qian Z.K., Cai X.S., Jiang Y., Huang W.D. The role of VE-cadherin in osteosarcoma cells. Pathol. Oncol. Res. 2010, 16:111-117.
43. Wrobel T., Mazur G., Wolowiec D., Jazwiec B., Sowinska E., Kuliczkowski K. SVE-cadherin and sCD146 serum levels in patients with multiple myeloma. Clin. Lab. Haematol. 2006, 28:36-39.
44. Habibagahi Z., Habibagahi M., Heidari M. Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease. Mod. Rheumatol. 2010, 20:154-159.
45. Villasante A., Pacheco E., Pau A., Ruiz A., Pellicer J.A., Garcia-Velasco Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum. Reprod. 2008, 23:662-667.
46. Parker B.S., Argani P., Cook B.P., Liangfeng H., Chartrand S.D., Zhang M., Saha S., Bardelli A., Jiang Y., St Martin T.B., Nacht M., Teicher B.A., Klinger K.W., Sukumar S., Madden S.L. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 2004, 64:7857-7866.
47. Kato K., Takada T., Fukusato T. Expression of vascular endothelial-cadherin in human hepatocellular carcinoma tissues. Hepatol. Res. 2007, 37:444-453.
48. Cavallaro U., Liebner S., Dejana E. Endothelial cadherins and tumor angiogenesis. Exp. Cell Res. 2006, 312:659-667.
49. Cheung K.L., Graves C.R., Robertson J.F. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 2000, 26:91-102.
50. Nicolini G., Tartarelli A., Carpi M.R., Metelli P., Ferrari L., Anselmi M., Conte P., Berti P., Miccoli Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6:269.
51. http://www.blood.co.uk.